Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>HSBC Research Expects CN Pharmas' 1H25 Sales to Hike by 10%+ in Avg., Raises TPs for Several Firms
Recommend 25 Positive 48 Negative 17 |
||||
|
||||
|
Chinese pharma outperformed the market YTD, HSBC Global Research issued a research report saying. The broker has been optimistic about the innovative drug sector since the beginning of the year, and expected the strong momentum to continue. HSBC Global Research forecasted the average product sales growth of the covered pharma companies to be about 11.2% in 1H25, in line with market consensus, as most BD projects signed in 1H25 will be booked in 2H25. In the long term, the average CAGR of leading pharmaceutical companies' earnings is expected to reach 18% for 2025-2027. The broker raised its target prices for Jiangsu HENGRUI PHARMA(600276.SH)/ HANSOH PHARMA (03692.HK)/ SINO BIOPHARM (01177.HK)/ CSPC PHARMA (01093.HK)/ CMS (00867.HK) to RMB70/ $45/ $8.49/ $10.7/ $16.1, with ratings kept at Buy. Furthermore, HSBC Global Research lifted its target prices for LIVZON PHARMA (01513.HK)'s H-/ A-shares to $37.54/ RMB44.16, and kept its target prices for FOSUN PHARMA (02196.HK)'s H-/ A-shares at $17.2/ RMB25.3 respectively, with all of which kept at Hold. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
